Lehigh Valley Hospital Pocono
Lehigh Valley Hospital Pocono was paid $11.90M by Medicaid between Jan 2018 and Dec 2024, across 256 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
EAST STROUDSBURG, PA 18301
Next to other Psychiatric Hospital Unit providers in Pennsylvania
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,347 | $108K | |
| 2019 | 1,933 | $113K | |
| 2020 | 27,158 | $964K | |
| 2021 | 120,450 | $4.32M | |
| 2022 | 42,285 | $2.20M | |
| 2023 | 51,626 | $2.31M | |
| 2024incomplete | 43,965 | $1.89M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 23,617 | 22,824 | $3.89M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 17,776 | 17,135 | $2.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 6,692 | 6,489 | $1.11M |
| G0378 | Hospital observation service, per hour | 3.2% | 541 | 398 | $379K |
| 80053 | Comprehensive metabolic panel | 2.4% | 28,317 | 26,403 | $288K |
| X0621 | 2.3% | 1,273 | 664 | $272K | |
| 80061 | Lipid panel | 1.6% | 13,414 | 13,263 | $191K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 2,325 | 2,206 | $179K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 1,962 | 1,903 | $162K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 1,143 | 1,126 | $162K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 26,720 | 24,267 | $131K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 1,528 | 1,525 | $126K |
244 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,736 | $114K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,697 | $111K |
| 76830 | Ultrasound, transvaginal | <1% | 2,395 | $111K |
| 80050 | General health panel | <1% | 2,305 | $107K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,671 | $95K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,161 | $92K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 793 | $75K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,548 | $66K |
| 86003 | <1% | 299 | $64K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 245 | $64K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 231 | $64K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 985 | $61K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,220 | $56K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,336 | $54K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,605 | $52K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,323 | $49K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 850 | $48K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 550 | $47K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 259 | $45K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,237 | $43K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,361 | $41K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 510 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,805 | $39K |
| 86803 | <1% | 1,750 | $35K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 147 | $35K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,059 | $34K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,526 | $33K |
| 94729 | <1% | 1,223 | $33K | |
| 76536 | <1% | 699 | $33K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 481 | $32K |
| 76642 | <1% | 738 | $32K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,502 | $31K |
| 72141 | <1% | 114 | $28K | |
| 77066 | Tomosynthesis, mammo | <1% | 318 | $28K |
| 80081 | <1% | 297 | $26K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 443 | $24K |
| 77065 | Tomosynthesis, mammo | <1% | 340 | $23K |
| 84702 | <1% | 1,264 | $22K | |
| 94727 | <1% | 1,209 | $21K | |
| 73221 | <1% | 79 | $21K | |
| 71250 | <1% | 387 | $20K | |
| 93971 | <1% | 287 | $19K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 558 | $18K |
| 85027 | <1% | 2,289 | $17K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 29 | $17K |
| 87631 | <1% | 162 | $17K | |
| 84439 | <1% | 2,040 | $17K | |
| 86780 | <1% | 989 | $16K | |
| 84484 | <1% | 2,185 | $16K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 456 | $16K |
| 86618 | <1% | 584 | $14K | |
| 450 | Pov group 1 hd 301-450 lbs | <1% | 43 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,346 | $14K |
| 84403 | <1% | 487 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,673 | $14K |
| 84466 | <1% | 779 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,353 | $13K |
| 82607 | <1% | 963 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,915 | $13K |
| 84146 | <1% | 502 | $13K | |
| 82728 | <1% | 1,002 | $12K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 25 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 214 | $11K |
| 93970 | <1% | 120 | $11K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 201 | $11K |
| 94060 | <1% | 1,232 | $11K | |
| 82570 | <1% | 1,548 | $11K | |
| 86038 | <1% | 617 | $10K | |
| 82043 | <1% | 1,224 | $10K | |
| 83001 | <1% | 516 | $9K | |
| 83525 | <1% | 755 | $9K | |
| 84270 | <1% | 332 | $9K | |
| 73564 | <1% | 401 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,129 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 350 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 350 | $8K |
| 81001 | <1% | 3,484 | $8K | |
| 83540 | <1% | 895 | $8K | |
| 83605 | <1% | 1,358 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 388 | $8K |
| 87340 | <1% | 487 | $7K | |
| 85610 | <1% | 2,288 | $7K | |
| 84703 | <1% | 906 | $7K | |
| 83002 | <1% | 406 | $7K | |
| 82670 | <1% | 318 | $7K | |
| 84153 | <1% | 282 | $7K | |
| 83690 | <1% | 1,869 | $7K | |
| 86850 | <1% | 947 | $7K | |
| 73610 | <1% | 378 | $7K | |
| 82627 | <1% | 294 | $7K | |
| 77062 | <1% | 288 | $6K | |
| 86617 | <1% | 277 | $6K | |
| 86706 | <1% | 448 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 57 | $6K |
| 70486 | <1% | 104 | $6K | |
| 72110 | <1% | 288 | $6K | |
| 82784 | <1% | 315 | $6K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 201 | $5K |
| 74246 | <1% | 123 | $5K | |
| 81003 | <1% | 1,793 | $5K | |
| 93017 | <1% | 164 | $5K | |
| 86480 | <1% | 66 | $5K | |
| 73630 | <1% | 449 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 46 | $4K |
| 83735 | <1% | 910 | $4K | |
| 76770 | <1% | 95 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 132 | $4K |
| 83970 | <1% | 112 | $4K | |
| 83021 | <1% | 188 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 93 | $4K |
| 82746 | <1% | 309 | $4K | |
| 73030 | <1% | 259 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,234 | $4K |
| 64483 | <1% | 29 | $4K | |
| 86431 | <1% | 446 | $4K | |
| 84140 | <1% | 128 | $4K | |
| 77061 | <1% | 153 | $3K | |
| 86901 | <1% | 969 | $3K | |
| 86800 | <1% | 177 | $3K | |
| 86900 | <1% | 970 | $3K | |
| 84144 | <1% | 209 | $3K | |
| 85730 | <1% | 515 | $3K | |
| 73130 | <1% | 305 | $3K | |
| 83880 | <1% | 143 | $3K | |
| 82533 | <1% | 245 | $3K | |
| 84550 | <1% | 479 | $3K | |
| 83655 | <1% | 258 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 161 | $3K |
| 85652 | <1% | 925 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 249 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,860 | $3K |
| 73110 | <1% | 249 | $3K | |
| 87536 | <1% | 26 | $3K | |
| 86235 | <1% | 142 | $3K | |
| 86200 | <1% | 175 | $3K | |
| 93226 | <1% | 63 | $3K | |
| 84460 | <1% | 331 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 48 | $2K |
| 300 | Patient transfer system <300 | <1% | 57 | $2K |
| 82950 | <1% | 346 | $2K | |
| 77080 | <1% | 48 | $2K | |
| 93880 | <1% | 30 | $2K | |
| 87634 | <1% | 29 | $2K | |
| 73502 | <1% | 139 | $2K | |
| 74018 | <1% | 179 | $2K | |
| 86695 | <1% | 108 | $2K | |
| 80076 | <1% | 238 | $2K | |
| 84480 | <1% | 257 | $2K | |
| 59025 | Fetal non-stress test | <1% | 97 | $2K |
| 72082 | <1% | 54 | $2K | |
| 86140 | <1% | 659 | $2K | |
| 83615 | <1% | 297 | $2K | |
| 86225 | <1% | 125 | $2K | |
| 87040 | <1% | 114 | $2K | |
| 96376 | <1% | 110 | $2K | |
| 86696 | <1% | 82 | $2K | |
| 82024 | <1% | 48 | $2K | |
| 76775 | <1% | 41 | $2K | |
| 85379 | <1% | 205 | $2K | |
| 86376 | <1% | 184 | $2K | |
| 86360 | <1% | 26 | $2K | |
| 82947 | <1% | 466 | $2K | |
| 84156 | <1% | 368 | $2K | |
| 72050 | <1% | 60 | $1K | |
| 93225 | <1% | 76 | $1K | |
| 85007 | <1% | 313 | $1K | |
| 86039 | <1% | 88 | $1K | |
| 84165 | <1% | 90 | $1K | |
| 87077 | <1% | 198 | $1K | |
| 84100 | <1% | 272 | $1K | |
| 82542 | <1% | 68 | $1K | |
| 86359 | <1% | 26 | $1K | |
| 87186 | <1% | 141 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,210 | $990.24 |
| 86704 | <1% | 57 | $967.35 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 151 | $891.72 |
| 80074 | <1% | 16 | $863.00 | |
| 82785 | <1% | 45 | $853.21 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,309 | $802.55 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,982 | $787.08 |
| A9270 | Non-covered item or service | <1% | 5,265 | $776.16 |
| 73140 | <1% | 87 | $724.93 | |
| 82550 | <1% | 104 | $705.58 | |
| 98968 | <1% | 26 | $694.96 | |
| 86708 | <1% | 42 | $656.06 | |
| 82248 | <1% | 93 | $623.68 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $598.78 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 18 | $570.00 |
| 93350 | <1% | 14 | $568.61 | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 38 | $567.60 |
| 84432 | <1% | 26 | $538.05 | |
| 76882 | <1% | 76 | $527.20 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 108 | $514.53 |
| 83516 | <1% | 12 | $513.00 | |
| 86769 | <1% | 27 | $430.84 | |
| 84481 | <1% | 16 | $423.70 | |
| 96523 | <1% | 29 | $413.66 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,559 | $398.41 |
| 84450 | <1% | 58 | $385.06 | |
| 84378 | <1% | 28 | $366.66 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 931 | $363.62 |
| 73590 | <1% | 25 | $355.65 | |
| 81025 | <1% | 160 | $344.90 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 304 | $318.23 |
| 90715 | <1% | 26 | $312.95 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,318 | $299.17 |
| 82150 | <1% | 56 | $294.73 | |
| 86255 | <1% | 13 | $293.74 | |
| 82948 | <1% | 214 | $275.48 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 14 | $257.37 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,665 | $243.29 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,541 | $225.37 |
| 73080 | <1% | 24 | $224.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 467 | $222.53 |
| OP250 | <1% | 53 | $206.25 | |
| J2704 | Injection, propofol, 10 mg | <1% | 171 | $197.30 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 27 | $184.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 443 | $159.93 |
| 96367 | <1% | 13 | $134.67 | |
| 85045 | <1% | 27 | $128.70 | |
| 87081 | <1% | 26 | $126.34 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,053 | $119.03 |
| 95819 | <1% | 12 | $101.65 | |
| 85018 | <1% | 29 | $80.53 | |
| 82962 | <1% | 70 | $70.88 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 400 | $65.31 |
| 85014 | <1% | 26 | $57.15 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 657 | $51.99 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 151 | $38.60 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 73 | $28.74 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 72 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 12 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 165 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 193 | $0.00 |
| J0517 | Injection, benralizumab, 1 mg | 0% | 12 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 100 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 159 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 18 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 440 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 223 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 82 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 25 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Millennium Health, LLC | San Diego, CA | $579.29M |
| Lehigh Valley Hospital | Allentown, PA | $64.40M |
| Lehigh Valley Hospital Hazleton | Hazleton, PA | $11.69M |
| Lehigh Valley Hospital | Allentown, PA | $10.00M |
| Lehigh Valley Hospital - Schuylkill | Pottsville, PA | $6.83M |
| Lehigh Valley Hospital- Pocono | Dickson City, PA | $3.75M |
| Lehigh Valley Hospital | Allentown, PA | $2.90M |
| Lehigh Valley Hospital | Allentown, PA | $1.95M |
| Lehigh Valley Hospital, INC | Allentown, PA | $1.85M |
| Lehigh Valley Hospital | Allentown, PA | $1.40M |
| Lehigh Valley Hospital - Schuylkill | Saint Clair, PA | $744K |
| Maryland Wound & Amputation Prevention, LLC | Lutherville, MD | $399K |
| Robert L Thomas MD FCCP LLC | Walterboro, SC | $253K |
| A-One Home Health Services, LLC | Everett, WA | $236K |
| Avamere Home Health Care, LLC | Bellingham, WA | $234K |
| Lehigh Valley Hospital Schuylkill | Pottsville, PA | $218K |
| Lehigh Valley Hospital Hazleton | Hazleton, PA | $193K |
| Prime Home Health, LLC | Federal Way, WA | $115K |
| Lehigh Valley Hospital | Allentown, PA | $70K |
| Northwest Hospice LLC | Tigard, OR | $33K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.